Veterinary drugmaker Virbac's H1 revenue rises on Supercharge platform strength

Virbac SA

20/07/2026 16:56

Overview
France animal health firm's H1 revenue rose 7.4% at constant rates, up 4.0% at actual rates
Growth driven by companion animal and farm animal segments, plus Supercharge platforms and Thyronorm acquisition
Company confirmed 2026 guidance at upper end of revenue growth range and 17% margin target

Outlook
Virbac targets upper end of 2026 revenue growth range of 5.5% to 7.5% at CERS
Company expects 2026 adjusted recurring operating income margin of around 17% at CERS
Virbac sees 2026 cash generation at about €80 mln, with capex of around €125 mln

Result Drivers
SUPERCHARGE PLATFORMS - Growth in petfood, reproduction, dental, mobility, ear, endocrinology, and ruminants supported results, especially in companion animal segment
THYRONORM ACQUISITION - Integration of Thyronorm boosted endocrinology range and contributed about 1.4 percentage points to overall growth
VOLUME/MIX AND PRICING - Solid volume/mix effect of about +5.4% and price increases of about +2% drove revenue growth

Company press release: ID:nGNEbmFGs2

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
EUR 384 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
Wall Street's median 12-month price target for Virbac SA is €413.50, about 26.8% above its July 17 closing price of €326.00
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)